{"gene":"TAP1","run_date":"2026-04-28T21:42:58","timeline":{"discoveries":[{"year":1992,"finding":"TAP1 is required for stable assembly and intracellular transport of MHC class I molecules; TAP1-deficient mice show severely reduced surface class I molecules and cannot present cytosolic antigens to class I-restricted cytotoxic T cells.","method":"Gene knockout (embryonic stem cell technology) with functional assays for antigen presentation and surface MHC class I expression","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — clean KO with multiple defined cellular phenotypes; foundational paper with 622 citations","pmids":["1473153"],"is_preprint":false},{"year":1993,"finding":"TAP1 is part of an ATP-dependent, sequence-specific peptide translocator; peptide translocation in vitro requires TAP1 and is both ATP-dependent and peptide selective.","method":"Cell-free in vitro peptide translocation assay using TAP1-deficient cell membranes","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstituted cell-free system demonstrating ATP-dependent, sequence-specific transport","pmids":["8348620"],"is_preprint":false},{"year":1994,"finding":"Both TAP1 and TAP2 subunits contribute to the peptide-recognition site (both are photolabeled by photopeptide analogues), but MHC class I/β2-microglobulin dimers associate specifically with TAP1 but not TAP2, indicating the MHC class I interaction site resides on TAP1. Efficient peptide binding requires coexpression of both TAP1 and TAP2, supporting heterodimeric function.","method":"Photoaffinity labeling of TAP subunits, co-immunoprecipitation of MHC class I with individual TAP subunits in transfectant cell lines","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (photoaffinity labeling + co-IP) in same study","pmids":["7809108"],"is_preprint":false},{"year":1994,"finding":"Introduction of the rat TAP1 gene alone into TAP1/TAP2-deficient CMT.64 cells restores CTL recognition of virus-infected cells, indicating that a TAP1 homodimer can partially translocate peptides into the ER.","method":"Gene transfection of TAP1 into antigen-processing deficient cell lines followed by CTL cytotoxicity assay","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 — clean gene rescue with defined functional readout; single lab","pmids":["7931074"],"is_preprint":false},{"year":1995,"finding":"TAP1 and LMP2 are divergently transcribed from a shared bidirectional promoter (~593 bp); an NF-κB element proximal to the TAP1 gene is required for TNF-α induction of both TAP1 and LMP2, and an adjacent GC box (binding Sp1) is required for basal expression of both genes.","method":"Bidirectional reporter assays, site-specific mutagenesis, in vivo genomic footprinting, in vitro binding studies (EMSA)","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including mutagenesis, reporter assays, and footprinting","pmids":["7699330"],"is_preprint":false},{"year":1996,"finding":"IFN-γ induction of TAP1 and LMP2 is mediated by IRF-1 binding to an IRF-E element in the shared bidirectional promoter; TAP1 and LMP2 expression are both greatly reduced in IRF-1-deficient mice, which also show reduced surface MHC class I and CD8+ T cells.","method":"In vivo footprinting, gel shift analysis (EMSA), gene knockout mice (IRF-1-/-) with functional readouts","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 1-2 — multiple methods including in vivo footprinting, EMSA, and KO mice","pmids":["8885869"],"is_preprint":false},{"year":1996,"finding":"IFN-γ induces TAP1 more rapidly than HLA class I by activating the TAP1 promoter via a GAS element bound by STAT1α (activated faster than IRF-1); the GAS element is necessary and sufficient for rapid IFN-γ response of TAP1.","method":"Promoter-reporter transfection assays, GAS element mutagenesis, kinetic analysis of STAT1α vs. IRF-1 activation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — promoter mutagenesis combined with kinetic signaling analysis; clear mechanistic dissection","pmids":["8617938"],"is_preprint":false},{"year":1996,"finding":"A functionally defective TAP1 allele (R659Q near the ATP-binding site) in a human small cell lung cancer cell line results in defective peptide transport and loss of MHC class I antigen presentation, restored by transfection of functional TAP1.","method":"Sequencing of TAP1 alleles, peptide binding assays, antigen presentation assays, gene transfection rescue","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including functional rescue by transfection","pmids":["8640228"],"is_preprint":false},{"year":1997,"finding":"EBV-encoded vIL-10 (and human IL-10) specifically downregulates expression of TAP1 and LMP2 (but not TAP2 or LMP7) in B lymphocytes, impairing peptide transport into the ER and reducing surface MHC class I expression.","method":"Gene expression analysis, TAP-specific peptide transporter assay, surface MHC class I measurement","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (expression, functional transport assay, surface MHC); strong specificity controls","pmids":["9310490"],"is_preprint":false},{"year":1997,"finding":"TAP1 membrane topology consists of eight transmembrane segments (based on E. coli expression of TAP1-β-lactamase fusions), with the N and C termini (including the nucleotide-binding domain) in the cytoplasm and several large loops exposed in the ER lumen.","method":"Reporter fusion (β-lactamase) topology mapping in E. coli","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — systematic topology mapping; later refined by cysteine-scanning study","pmids":["9111005"],"is_preprint":false},{"year":1998,"finding":"IFN-α/β and IFN-γ both regulate TAP1 through GAS and ISRE elements; the phosphatase SHP-1 (expressed at lower levels in endothelial cells than HeLa cells) regulates crossover signaling between IFN-α/β and IFN-γ pathways at the TAP1 promoter.","method":"Promoter-reporter assays, overexpression of dominant negative SHP-1, kinase/signaling analysis in endothelial cells vs. HeLa cells","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic dissection of signaling crossover with functional promoter readout; single lab","pmids":["9776728"],"is_preprint":false},{"year":1999,"finding":"p53 directly induces TAP1 expression through a p53-responsive element in the TAP1 gene; p53-induced TAP1 enhances peptide transport and surface MHC class I-peptide complex expression, with cooperation between p53 and IFN-γ in activating the MHC class I pathway.","method":"Reporter assays with p53-responsive element, p53/p73 transfection, peptide transport assays, surface MHC class I measurement","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods including reporter assays, functional transport assay, and surface expression","pmids":["10618714"],"is_preprint":false},{"year":1999,"finding":"TAP1 deficiency in human patients causes unstable HLA class I molecules retained in the endoplasmic reticulum, leading to HLA class I deficiency syndrome (bare lymphocyte syndrome type I) with lung and skin manifestations.","method":"Clinical patient analysis, protein biochemistry, HLA class I stability assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function with defined molecular phenotype (ER retention of class I)","pmids":["10074495"],"is_preprint":false},{"year":2000,"finding":"Walker A lysine mutations in the nucleotide-binding domains of TAP1 (K544M) and TAP2 (K509M) block peptide translocation but not peptide binding; nucleotide binding to TAP1 is not required for peptide binding, and both intact NBDs are needed for efficient peptide translocation.","method":"Site-directed mutagenesis, nucleotide binding assays, fluorescence quenching peptide binding assays, peptide translocation assays in insect cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro mutagenesis with multiple functional assays (binding and translocation) dissecting distinct NBD roles","pmids":["11099504"],"is_preprint":false},{"year":2001,"finding":"The ABC ATPase domain of TAP1 (cTAP1) forms an L-shaped molecule with a RecA-like domain and a small α-helical domain; the ADP diphosphate group interacts with the P-loop; residues involved in γ-phosphate binding and hydrolysis show flexibility in the ADP-bound state; TAP1 differs from TAP2 in the nucleotide-binding site, potentially explaining asymmetry during peptide transport.","method":"X-ray crystallography of the C-terminal ABC ATPase domain of TAP1 bound to ADP","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with functional comparison across subfamily members","pmids":["11532960"],"is_preprint":false},{"year":2001,"finding":"HPV type 11 E7 protein physically interacts with TAP1 (co-immunoprecipitation with calreticulin and TAP1; anti-TAP1 antibody co-precipitates E7) and inhibits ATP-dependent peptide transport in vitro.","method":"Co-immunoprecipitation, in vitro ATP-dependent peptide transport assay with purified HPV11 E7 protein","journal":"Clinical immunology","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding by co-IP and in vitro inhibition of transport confirmed","pmids":["11580231"],"is_preprint":false},{"year":2002,"finding":"Tapasin interacts with the membrane-spanning domains (not the nucleotide-binding domains) of both TAP1 and TAP2; tapasin is not required for high-affinity peptide binding to TAP but enhances structural/thermal stability of TAP1·TAP2 complexes, explaining how tapasin increases TAP protein expression levels.","method":"Co-immunoprecipitation, domain-swapped chimeras, truncated TAP constructs, thermostability assays in insect cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple domain constructs with functional assays identify the interaction interface and functional consequence","pmids":["12213826"],"is_preprint":false},{"year":2003,"finding":"A single-nucleotide deletion at position +1489 of TAP1 in a melanoma cell line causes rapid degradation of TAP1 mRNA (>2-fold decrease in half-life) via a non-NMD pathway, leading to loss of TAP1 expression and MHC class I downregulation despite active TAP1 transcription.","method":"Tet-Off inducible expression system to measure mRNA half-life, cycloheximide chase, sequencing","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — quantitative mRNA half-life measurement with mechanistic controls ruling out NMD","pmids":["12582163"],"is_preprint":false},{"year":2004,"finding":"IFN-γ induction of murine Tap-1 and Lmp-2 in macrophages requires both STAT1 (binding the proximal GAS box rapidly) and IRF-1 (binding the IRF-1 box after ≥2h); in STAT1 knockout macrophages, IFN-γ fails to induce Tap-1 or Lmp-2.","method":"Promoter deletion analysis, EMSA with nuclear extracts, gene knockout mice (STAT1-/-), IFN-γ stimulation assays","journal":"Genes and immunity","confidence":"High","confidence_rationale":"Tier 1-2 — multiple methods including KO mice and EMSA identifying sequential transcription factor binding","pmids":["14735146"],"is_preprint":false},{"year":2006,"finding":"TAP1 contains ten transmembrane segments within an assembled functional peptide-loading complex, placing both N and C termini in the cytosol; the TM domain consists of a core of six TMs (conserved among ABC transporters) plus a unique N-terminal domain of four TMs essential for tapasin binding and peptide-loading complex assembly.","method":"Cysteine-scanning mutagenesis with membrane-impermeable thiol-specific fluorophores in semi-permeabilized living cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic cysteine-scanning in intact functional complex provides refined topology map with functional validation","pmids":["16407277"],"is_preprint":false},{"year":2006,"finding":"TAP biogenesis requires assembly of pre-existing TAP1 with newly synthesized TAP2 (not vice versa); the pore-forming core transmembrane domain of TAP2 is necessary and sufficient for assembly with pre-existing TAP1; TAP2 is rapidly degraded when expressed alone but is stabilized upon heterodimerization with TAP1.","method":"In vitro expression system, pulse-chase analysis, domain truncation of TAP2, functional transport assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with domain mapping and functional readout","pmids":["16624807"],"is_preprint":false},{"year":2006,"finding":"The catalytic site of TAP1 contains non-consensus residues (Asp668 in Walker B, Gln701 in switch region) that attenuate ATPase activity at the TAP1 nucleotide-binding site; the TAP2 site (with Glu632 and His661) is the primary catalytically active site driving peptide transport.","method":"Site-directed mutagenesis of catalytic site residues, peptide translocation assays, MHC class I surface expression assays in insect cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — systematic mutagenesis of both catalytic sites with quantitative functional readouts","pmids":["17068338"],"is_preprint":false},{"year":2007,"finding":"The C terminus of TAP1 (last five residues) modulates TAP function as part of the dimer interface of the nucleotide-binding domains; antibody binding to this region arrests TAP in a peptide transport-incompetent conformation while ATP and peptide binding to TAP remain unaffected.","method":"Recombinant antibody (Fv and Fab) generation, epitope mapping by solid-supported peptide arrays, surface plasmon resonance, peptide transport assays","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — functional consequence of C-terminus binding demonstrated; single lab","pmids":["17418234"],"is_preprint":false},{"year":2007,"finding":"TAP1 indirectly regulates CD4+ T cell priming during Toxoplasma gondii infection by controlling NK cell IFN-γ production; adoptive transfer of IFN-γ-competent NK cells into TAP1-/- mice restores CD4+ T cell IFN-γ responses, placing TAP1 upstream of NK cell licensing in innate immune signaling.","method":"TAP1-/- mouse infection model, NK cell depletion, adoptive transfer of IFN-γ+/+ vs. IFN-γ-/- NK cells, flow cytometry","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis by adoptive transfer with mechanistic dissection of NK-CD4 axis","pmids":["17923502"],"is_preprint":false},{"year":2011,"finding":"Low basal TAP1 expression in SCCHN cells is primarily regulated by deficient STAT1 phosphorylation (pSTAT1); STAT1 knockdown reduces IFN-γ-mediated TAP1 expression and CTL recognition; pSTAT3 does not interfere with IFN-γ-induced STAT1 binding to the TAP1 promoter or TAP1 expression.","method":"STAT1 knockdown/overexpression, IFN-γ stimulation, CTL recognition assays, chromatin immunoprecipitation (STAT1 binding to TAP1 promoter)","journal":"Cancer immunology, immunotherapy","confidence":"Medium","confidence_rationale":"Tier 2 — multiple methods including ChIP for STAT1 at TAP1 promoter; single lab","pmids":["21207025"],"is_preprint":false},{"year":2013,"finding":"TAP1 (ABCB2) is a downstream transcriptional target of SHH/GLI1/2 hedgehog signaling; GLI1/2 binds to the TAP1 promoter, and TAP1 mediates hedgehog-induced drug resistance in pancreatic ductal adenocarcinoma cells.","method":"ChIP and promoter binding assays (GLI-binding site validation), RNAi knockdown of GLI1 and TAP1, in vitro and in vivo tumor drug sensitivity assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — GLI binding to TAP1 promoter confirmed by molecular assay with functional drug resistance readout; single lab","pmids":["23340176"],"is_preprint":false},{"year":2018,"finding":"Naturally occurring TAP1 polymorphic variants have no or limited effect on peptide transport or MHC class I expression, and herpesvirus-encoded TAP inhibitors (HCMV US6, HSV-1 ICP47, EBV BNLF2a) inhibit a broad spectrum of TAP variants without allele-specific resistance.","method":"Peptide transport assays, MHC class I surface expression assays across TAP1/TAP2 variant-expressing cells, viral TAP inhibitor inhibition assays","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — systematic functional testing across natural variants with multiple inhibitors; single lab","pmids":["29879547"],"is_preprint":false},{"year":2020,"finding":"miR-200a-5p directly targets the 3'-UTR of TAP1, reducing TAP1 protein levels and HLA class I surface expression in melanoma cells, leading to enhanced NK cell sensitivity; miR-200a-5p expression is inversely correlated with TAP1 protein in melanoma cell lines and primary lesions.","method":"Luciferase reporter assay (miR binding to TAP1 3'-UTR), miR overexpression/inhibitor experiments, surface HLA-I measurement, NK cell killing assay","journal":"Oncoimmunology","confidence":"High","confidence_rationale":"Tier 1-2 — validated by luciferase reporter assay plus functional consequences in multiple assays","pmids":["32923135"],"is_preprint":false},{"year":2020,"finding":"Hedgehog transcription factor GLI1/2 directly binds to the TAP1 promoter and transcriptionally controls TAP1 expression in hepatocellular carcinoma, mediating drug resistance to sorafenib, doxorubicin, and cisplatin.","method":"ChIP/promoter binding assays (GLI-binding site in TAP1 promoter), RNAi of GLI1 and TAP1, drug sensitivity assays in vitro and in vivo","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding validated with functional drug resistance readout; single lab","pmids":["32108992"],"is_preprint":false},{"year":2021,"finding":"TAP1 promotes IFN-β production by activating TBK1 and IRF3 signaling, conferring broad antiviral activity against multiple viruses (HSV-1, AdV, VSV, DENV, ZIKV, influenza) independent of its antigen presentation function.","method":"Loss-of-function and gain-of-function experiments, IFN-β reporter assays, TBK1/IRF3 activation assays, viral infection assays","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal experiments; novel function claim requires independent replication","pmids":["33925089"],"is_preprint":false}],"current_model":"TAP1 (ABCB2) is an ER-resident ABC transporter that forms a heterodimer with TAP2, using ATP hydrolysis (driven primarily by the TAP2 nucleotide-binding site, with TAP1's NBD playing an asymmetric, attenuated catalytic role) to translocate cytosolic antigenic peptides across the ER membrane for loading onto MHC class I molecules; its expression is transcriptionally regulated by a shared bidirectional promoter with LMP2 via STAT1, IRF-1, NF-κB, and Sp1 elements downstream of IFN-γ/TNF-α signaling, TAP1 protein stability depends on heterodimerization with TAP2 (stabilized by tapasin binding to the N-terminal four-TM domain), MHC class I molecules interact specifically with TAP1 (not TAP2), and TAP1 is targeted by viral immune evasion proteins (e.g., HPV E7, HSV ICP47) and post-transcriptionally regulated by miRNAs (miR-200a-5p, miR-26b-5p, miR-21-3p), with an additional emerging role in innate antiviral signaling through TBK1-IRF3-mediated IFN-β production."},"narrative":{"teleology":[{"year":1992,"claim":"Establishing that TAP1 is non-redundant for MHC class I surface expression and antigen presentation resolved whether this MHC-linked gene was truly essential for the class I pathway.","evidence":"TAP1 knockout mice generated by ES cell technology showed severely reduced surface class I and abolished CTL recognition of cytosolic antigens","pmids":["1473153"],"confidence":"High","gaps":["Mechanism of peptide transport not yet demonstrated biochemically","Relative contributions of TAP1 vs TAP2 unknown"]},{"year":1993,"claim":"Demonstrating ATP-dependent, sequence-selective peptide translocation in a cell-free system established TAP1 as part of a bona fide active transporter rather than a passive channel.","evidence":"In vitro peptide translocation assay using membranes from TAP1-deficient cells reconstituted with TAP1","pmids":["8348620"],"confidence":"High","gaps":["Whether TAP1 alone or TAP1–TAP2 heterodimer is the functional unit not resolved","Substrate selectivity rules incomplete"]},{"year":1994,"claim":"Photoaffinity labeling and co-IP showed that both TAP1 and TAP2 contact peptide, but MHC class I associates specifically with TAP1, assigning distinct roles within the heterodimer.","evidence":"Photoaffinity peptide labeling of individual TAP subunits and co-immunoprecipitation of MHC class I with TAP1 but not TAP2 in transfectant lines","pmids":["7809108"],"confidence":"High","gaps":["Structural basis for selective MHC class I–TAP1 interaction unknown","Stoichiometry of MHC class I–TAP complex not determined"]},{"year":1995,"claim":"Identification of the shared bidirectional TAP1–LMP2 promoter with NF-κB and Sp1 elements explained coordinated regulation of antigen processing genes by inflammatory cytokines.","evidence":"Bidirectional reporter assays, site-directed mutagenesis of NF-κB and GC elements, in vivo footprinting, and EMSA","pmids":["7699330"],"confidence":"High","gaps":["Full set of transcription factors using this promoter not catalogued","Chromatin context and epigenetic regulation not addressed"]},{"year":1996,"claim":"Sequential engagement of STAT1 (via GAS element) and IRF-1 (via IRF-E) explained how IFN-γ rapidly and sustainably induces TAP1, with KO mice confirming both factors are required in vivo.","evidence":"Promoter mutagenesis, kinetic signaling analysis of STAT1α vs IRF-1 activation; IRF-1−/− and later STAT1−/− mice showing loss of TAP1 induction","pmids":["8617938","8885869","14735146"],"confidence":"High","gaps":["Epigenetic mechanisms governing promoter accessibility not explored","Whether other STAT family members compensate partially unclear"]},{"year":1996,"claim":"Identification of a human TAP1 point mutation (R659Q) near the ATP-binding site that abolished peptide transport in a lung cancer line established that single residue changes in the NBD are sufficient to eliminate function.","evidence":"Sequencing, peptide binding assays, and gene transfection rescue of antigen presentation in a small cell lung cancer line","pmids":["8640228"],"confidence":"High","gaps":["Whether this mutation affects ATP binding, hydrolysis, or conformational coupling not distinguished"]},{"year":1999,"claim":"Discovery that p53 directly transactivates TAP1 via a p53-responsive element linked tumor suppression to immune surveillance through antigen processing.","evidence":"Reporter assays with p53-responsive element, p53 transfection, peptide transport and surface MHC class I assays","pmids":["10618714"],"confidence":"High","gaps":["Whether p53 loss in tumors is a dominant mechanism of TAP1 silencing in vivo not tested","Interaction with other p53 family members (p73) only partially explored"]},{"year":1999,"claim":"TAP1 deficiency in humans was shown to cause bare lymphocyte syndrome type I with ER-retained unstable HLA class I, directly linking TAP1 loss to a defined immunodeficiency.","evidence":"Clinical analysis of TAP1-deficient patients with biochemical demonstration of ER-retained class I molecules","pmids":["10074495"],"confidence":"High","gaps":["Genotype-phenotype correlation across different TAP1 mutations incomplete","Why patients develop granulomatous lung disease specifically not mechanistically explained"]},{"year":2001,"claim":"The crystal structure of the TAP1 NBD revealed an L-shaped RecA-like/α-helical architecture with non-consensus catalytic residues, providing the structural basis for asymmetric ATPase activity in the TAP heterodimer.","evidence":"X-ray crystallography of the C-terminal ATPase domain of TAP1 bound to ADP","pmids":["11532960"],"confidence":"High","gaps":["Full-length TAP1–TAP2 heterodimer structure not available","Conformational changes during the transport cycle not captured"]},{"year":2001,"claim":"HPV E7 was shown to physically bind TAP1 and inhibit ATP-dependent peptide transport, establishing a viral immune evasion mechanism directly targeting the transporter.","evidence":"Co-immunoprecipitation of HPV11 E7 with TAP1, in vitro peptide transport inhibition assay","pmids":["11580231"],"confidence":"High","gaps":["Binding interface on TAP1 not mapped","Mechanism of transport inhibition (competitive vs allosteric) not determined"]},{"year":2002,"claim":"Tapasin was found to bind the transmembrane domains (not NBDs) of TAP1 and TAP2 and to stabilize the heterodimer thermally, explaining how tapasin enhances TAP protein levels without affecting peptide binding affinity.","evidence":"Co-immunoprecipitation with domain-swapped chimeras, truncated TAP constructs, and thermostability assays in insect cells","pmids":["12213826"],"confidence":"High","gaps":["Precise TM helices mediating tapasin contact not identified","How tapasin stabilization coordinates with peptide loading kinetics unclear"]},{"year":2006,"claim":"Refined topology mapping established TAP1 as a 10-TM protein with a unique N-terminal four-TM domain essential for tapasin binding and peptide-loading complex assembly, distinguishing it from canonical six-TM ABC transporters.","evidence":"Cysteine-scanning mutagenesis with membrane-impermeable fluorophores in semi-permeabilized cells expressing functional peptide-loading complex","pmids":["16407277"],"confidence":"High","gaps":["High-resolution structure of the N-terminal four-TM domain not available","Whether the N-terminal domain contacts MHC class I directly not tested"]},{"year":2006,"claim":"Mutagenesis of both catalytic sites showed TAP1's NBD has attenuated ATPase activity due to non-consensus Walker B (Asp668) and switch (Gln701) residues, assigning TAP2's NBD as the primary catalytic engine for peptide translocation.","evidence":"Site-directed mutagenesis of catalytic residues in both NBDs, quantitative peptide translocation and MHC class I surface expression assays","pmids":["17068338"],"confidence":"High","gaps":["Whether TAP1 NBD contributes regulatory ATP binding without hydrolysis not fully resolved","Coupling mechanism between TAP2 hydrolysis and conformational switching of TAP1 TMDs not defined"]},{"year":2020,"claim":"miR-200a-5p was validated as a direct post-transcriptional repressor of TAP1 via its 3′-UTR, revealing a microRNA-based mechanism for immune evasion in melanoma.","evidence":"Luciferase reporter assay confirming miR-200a-5p binding to TAP1 3′-UTR, miR overexpression/inhibition with HLA-I surface measurement and NK cell killing assays","pmids":["32923135"],"confidence":"High","gaps":["Whether other miRNAs (miR-26b-5p, miR-21-3p) act additively on TAP1 not established","In vivo relevance of miR-200a-5p–TAP1 axis in tumor immune evasion not demonstrated"]},{"year":2021,"claim":"A presentation-independent innate immune role was proposed for TAP1, activating TBK1–IRF3 signaling to induce IFN-β and confer broad antiviral activity.","evidence":"Loss- and gain-of-function experiments, IFN-β reporter assays, TBK1/IRF3 activation, and multi-virus infection assays","pmids":["33925089"],"confidence":"Medium","gaps":["Not independently replicated","Molecular mechanism by which TAP1 activates TBK1 unknown","Whether this function requires TAP2 not determined"]},{"year":null,"claim":"A high-resolution structure of the full-length TAP1–TAP2 heterodimer in complex with tapasin and MHC class I capturing multiple conformational states during the transport cycle remains unresolved, as does the precise mechanism by which TAP1 activates TBK1–IRF3 signaling independently of peptide transport.","evidence":"","pmids":[],"confidence":"High","gaps":["No full transport-cycle structural snapshots of the human TAP1–TAP2–tapasin–MHC I complex","Mechanism of TAP1-mediated TBK1 activation uncharacterized","Relative contributions of transcriptional vs post-transcriptional TAP1 silencing in tumor immune evasion in vivo not quantified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[1,13,14,21]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,3,13,21]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[9,12,19]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[19]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,12,23]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[1,13,21]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5,6,11,18]}],"complexes":["TAP1–TAP2 heterodimer","MHC class I peptide-loading complex"],"partners":["TAP2","TAPBP","B2M","IRF1","STAT1","GLI1"],"other_free_text":[]},"mechanistic_narrative":"TAP1 is an ER-resident ABC transporter subunit that heterodimerizes with TAP2 to form an ATP-dependent peptide translocator essential for loading antigenic peptides onto MHC class I molecules and sustaining cell-surface class I expression [PMID:1473153, PMID:8348620]. Both subunits contribute to the peptide-binding site, but MHC class I heavy chain–β2-microglobulin dimers associate specifically with TAP1; the TAP1 nucleotide-binding domain adopts a non-consensus catalytic configuration with attenuated ATPase activity, making the TAP2 NBD the primary driver of transport, while the N-terminal four-transmembrane domain unique to TAP1 mediates tapasin binding and peptide-loading complex assembly [PMID:7809108, PMID:17068338, PMID:16407277]. Transcription of TAP1 is governed by a bidirectional promoter shared with LMP2, integrating IFN-γ signals through sequential STAT1 (GAS element) and IRF-1 engagement, NF-κB-dependent TNF-α responses, and p53-mediated induction, while post-transcriptionally TAP1 is regulated by miR-200a-5p targeting its 3′-UTR [PMID:7699330, PMID:8617938, PMID:8885869, PMID:10618714, PMID:32923135]. Loss-of-function mutations in TAP1 cause bare lymphocyte syndrome type I (HLA class I deficiency) with pulmonary and cutaneous disease [PMID:10074495]."},"prefetch_data":{"uniprot":{"accession":"Q03518","full_name":"Antigen peptide transporter 1","aliases":["ATP-binding cassette sub-family B member 2","Peptide supply factor 1","Peptide transporter PSF1","PSF-1","Peptide transporter TAP1","Peptide transporter involved in antigen processing 1","Really interesting new gene 4 protein","RING4"],"length_aa":748,"mass_kda":81.0,"function":"ABC transporter associated with antigen processing. In complex with TAP2 mediates unidirectional translocation of peptide antigens from cytosol to endoplasmic reticulum (ER) for loading onto MHC class I (MHCI) molecules (PubMed:25377891, PubMed:25656091). Uses the chemical energy of ATP to export peptides against the concentration gradient (PubMed:25377891). During the transport cycle alternates between 'inward-facing' state with peptide binding site facing the cytosol to 'outward-facing' state with peptide binding site facing the ER lumen. Peptide antigen binding to ATP-loaded TAP1-TAP2 induces a switch to hydrolysis-competent 'outward-facing' conformation ready for peptide loading onto nascent MHCI molecules. Subsequently ATP hydrolysis resets the transporter to the 'inward facing' state for a new cycle (PubMed:11274390, PubMed:25377891, PubMed:25656091). Typically transports intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via IFNG-induced immunoproteasome. Binds peptides with free N- and C-termini, the first three and the C-terminal residues being critical. Preferentially selects peptides having a highly hydrophobic residue at position 3 and hydrophobic or charged residues at the C-terminal anchor. Proline at position 2 has the most destabilizing effect (PubMed:11274390, PubMed:7500034, PubMed:9256420). As a component of the peptide loading complex (PLC), acts as a molecular scaffold essential for peptide-MHCI assembly and antigen presentation (PubMed:1538751, PubMed:25377891, PubMed:26611325)","subcellular_location":"Endoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/Q03518/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TAP1","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2},{"gene":"GDI1","stoichiometry":0.2},{"gene":"CCDC47","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TAP1","total_profiled":1310},"omim":[{"mim_id":"613537","title":"NLR FAMILY, CASPASE RECRUITMENT DOMAIN-CONTAINING 5; NLRC5","url":"https://www.omim.org/entry/613537"},{"mim_id":"612824","title":"SEC14-LIKE LIPID-BINDING PROTEIN 3; SEC14L3","url":"https://www.omim.org/entry/612824"},{"mim_id":"609960","title":"PUMILIO RNA-BINDING FAMILY, MEMBER 3; PUM3","url":"https://www.omim.org/entry/609960"},{"mim_id":"607558","title":"SEC14-LIKE LIPID-BINDING PROTEIN 2; SEC14L2","url":"https://www.omim.org/entry/607558"},{"mim_id":"605464","title":"ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 8; ABCB8","url":"https://www.omim.org/entry/605464"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"},{"location":"Centriolar satellite","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TAP1"},"hgnc":{"alias_symbol":["PSF1","RING4","D6S114E"],"prev_symbol":["ABCB2"]},"alphafold":{"accession":"Q03518","domains":[{"cath_id":"-","chopping":"81-140_148-174_193-218","consensus_level":"medium","plddt":63.8732,"start":81,"end":218},{"cath_id":"1.20.1560.10","chopping":"237-380","consensus_level":"medium","plddt":87.5494,"start":237,"end":380},{"cath_id":"3.40.50.300","chopping":"562-800","consensus_level":"medium","plddt":89.3807,"start":562,"end":800}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03518","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q03518-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q03518-F1-predicted_aligned_error_v6.png","plddt_mean":78.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TAP1","jax_strain_url":"https://www.jax.org/strain/search?query=TAP1"},"sequence":{"accession":"Q03518","fasta_url":"https://rest.uniprot.org/uniprotkb/Q03518.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q03518/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q03518"}},"corpus_meta":[{"pmid":"1473153","id":"PMC_1473153","title":"TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells.","date":"1992","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/1473153","citation_count":622,"is_preprint":false},{"pmid":"8348620","id":"PMC_8348620","title":"TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8348620","citation_count":329,"is_preprint":false},{"pmid":"8270878","id":"PMC_8270878","title":"Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8270878","citation_count":295,"is_preprint":false},{"pmid":"10377193","id":"PMC_10377193","title":"Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium tuberculosis.","date":"1999","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10377193","citation_count":276,"is_preprint":false},{"pmid":"11532960","id":"PMC_11532960","title":"Structure of the ABC ATPase domain of human TAP1, the transporter associated with antigen processing.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11532960","citation_count":234,"is_preprint":false},{"pmid":"8428770","id":"PMC_8428770","title":"Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2.","date":"1993","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8428770","citation_count":227,"is_preprint":false},{"pmid":"8833913","id":"PMC_8833913","title":"Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen.","date":"1996","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/8833913","citation_count":227,"is_preprint":false},{"pmid":"7699330","id":"PMC_7699330","title":"Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7699330","citation_count":208,"is_preprint":false},{"pmid":"8546899","id":"PMC_8546899","title":"Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer.","date":"1996","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8546899","citation_count":164,"is_preprint":false},{"pmid":"8640228","id":"PMC_8640228","title":"A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8640228","citation_count":164,"is_preprint":false},{"pmid":"9310490","id":"PMC_9310490","title":"Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Barr virus-encoded interleukin-10.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9310490","citation_count":158,"is_preprint":false},{"pmid":"7809108","id":"PMC_7809108","title":"Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2).","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7809108","citation_count":152,"is_preprint":false},{"pmid":"7640226","id":"PMC_7640226","title":"Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression.","date":"1995","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/7640226","citation_count":150,"is_preprint":false},{"pmid":"9485029","id":"PMC_9485029","title":"HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.","date":"1998","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/9485029","citation_count":144,"is_preprint":false},{"pmid":"11039910","id":"PMC_11039910","title":"Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11039910","citation_count":127,"is_preprint":false},{"pmid":"8198988","id":"PMC_8198988","title":"Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.","date":"1994","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8198988","citation_count":125,"is_preprint":false},{"pmid":"8885869","id":"PMC_8885869","title":"Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1-/- mice.","date":"1996","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/8885869","citation_count":123,"is_preprint":false},{"pmid":"10618714","id":"PMC_10618714","title":"p53 induces TAP1 and enhances the transport of MHC class I peptides.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10618714","citation_count":101,"is_preprint":false},{"pmid":"10074495","id":"PMC_10074495","title":"HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1.","date":"1999","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/10074495","citation_count":97,"is_preprint":false},{"pmid":"8617938","id":"PMC_8617938","title":"Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8617938","citation_count":91,"is_preprint":false},{"pmid":"21207025","id":"PMC_21207025","title":"Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes.","date":"2011","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/21207025","citation_count":89,"is_preprint":false},{"pmid":"7931074","id":"PMC_7931074","title":"Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7931074","citation_count":82,"is_preprint":false},{"pmid":"8022815","id":"PMC_8022815","title":"Altered natural killer cell repertoire in Tap-1 mutant mice.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8022815","citation_count":81,"is_preprint":false},{"pmid":"16287864","id":"PMC_16287864","title":"PSF1 is essential for early embryogenesis in mice.","date":"2005","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16287864","citation_count":75,"is_preprint":false},{"pmid":"11099504","id":"PMC_11099504","title":"Walker A lysine mutations of TAP1 and TAP2 interfere with peptide translocation but not peptide binding.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11099504","citation_count":64,"is_preprint":false},{"pmid":"9815722","id":"PMC_9815722","title":"IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.","date":"1997","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9815722","citation_count":62,"is_preprint":false},{"pmid":"14735146","id":"PMC_14735146","title":"Regulation of murine Tap1 and Lmp2 genes in macrophages by interferon gamma is mediated by STAT1 and IRF-1.","date":"2004","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/14735146","citation_count":61,"is_preprint":false},{"pmid":"8022816","id":"PMC_8022816","title":"Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8022816","citation_count":61,"is_preprint":false},{"pmid":"20103637","id":"PMC_20103637","title":"PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties.","date":"2010","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/20103637","citation_count":59,"is_preprint":false},{"pmid":"11580231","id":"PMC_11580231","title":"Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport.","date":"2001","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/11580231","citation_count":58,"is_preprint":false},{"pmid":"9952025","id":"PMC_9952025","title":"Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I).","date":"1999","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9952025","citation_count":56,"is_preprint":false},{"pmid":"8764046","id":"PMC_8764046","title":"Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8764046","citation_count":56,"is_preprint":false},{"pmid":"8609387","id":"PMC_8609387","title":"Development of CD8 alpha alpha+ intestinal intraepithelial T cells in beta 2-microglobulin- and/or TAP1-deficient mice.","date":"1996","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8609387","citation_count":55,"is_preprint":false},{"pmid":"17923502","id":"PMC_17923502","title":"TAP-1 indirectly regulates CD4+ T cell priming in Toxoplasma gondii infection by controlling NK cell IFN-gamma production.","date":"2007","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17923502","citation_count":55,"is_preprint":false},{"pmid":"10471632","id":"PMC_10471632","title":"Analysis of MHC encoded antigen-processing genes TAP1 and TAP2 polymorphisms in sarcoidosis.","date":"1999","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10471632","citation_count":52,"is_preprint":false},{"pmid":"3693407","id":"PMC_3693407","title":"Nerve terminal anchorage protein 1 (TAP-1) is a chondroitin sulfate proteoglycan: biochemical and electron microscopic characterization.","date":"1987","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/3693407","citation_count":52,"is_preprint":false},{"pmid":"29341428","id":"PMC_29341428","title":"Epigenetic Silencing of TAP1 in Aldefluor+ Breast Cancer Stem Cells Contributes to Their Enhanced Immune Evasion.","date":"2018","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/29341428","citation_count":51,"is_preprint":false},{"pmid":"10368149","id":"PMC_10368149","title":"Insertional inactivation of Treponema denticola tap1 results in a nonmotile mutant with elongated flagellar hooks.","date":"1999","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/10368149","citation_count":51,"is_preprint":false},{"pmid":"15944272","id":"PMC_15944272","title":"Mouse endothelial cells cross-present lymphocyte-derived antigen on class I MHC via a TAP1- and proteasome-dependent pathway.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15944272","citation_count":47,"is_preprint":false},{"pmid":"7678769","id":"PMC_7678769","title":"Induction of a tomato anionic peroxidase gene (tap1) by wounding in transgenic tobacco and activation of tap1/GUS and tap2/GUS chimeric gene fusions in transgenic tobacco by wounding and pathogen attack.","date":"1993","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7678769","citation_count":47,"is_preprint":false},{"pmid":"16634865","id":"PMC_16634865","title":"Analysis of IL1B, TAP1, TAP2 and IKBL polymorphisms on susceptibility to tuberculosis.","date":"2006","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16634865","citation_count":46,"is_preprint":false},{"pmid":"10618282","id":"PMC_10618282","title":"Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease.","date":"2000","source":"Clinical and diagnostic laboratory immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10618282","citation_count":46,"is_preprint":false},{"pmid":"19607757","id":"PMC_19607757","title":"Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice.","date":"2009","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19607757","citation_count":45,"is_preprint":false},{"pmid":"1680216","id":"PMC_1680216","title":"Molecular characterization of two stamen-specific genes, tap1 and fil1, that are expressed in the wild type, but not in the deficiens mutant of Antirrhinum majus.","date":"1991","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/1680216","citation_count":45,"is_preprint":false},{"pmid":"20825491","id":"PMC_20825491","title":"Up-regulation of PSF1 promotes the growth of breast cancer cells.","date":"2010","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/20825491","citation_count":43,"is_preprint":false},{"pmid":"12213826","id":"PMC_12213826","title":"Tapasin interacts with the membrane-spanning domains of both TAP subunits and enhances the structural stability of TAP1 x TAP2 Complexes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12213826","citation_count":43,"is_preprint":false},{"pmid":"23340176","id":"PMC_23340176","title":"ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23340176","citation_count":42,"is_preprint":false},{"pmid":"12582163","id":"PMC_12582163","title":"A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12582163","citation_count":42,"is_preprint":false},{"pmid":"19609238","id":"PMC_19609238","title":"Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function.","date":"2009","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/19609238","citation_count":41,"is_preprint":false},{"pmid":"9027960","id":"PMC_9027960","title":"Polymorphisms of TAP1 and TAP2 genes in Graves' disease.","date":"1997","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/9027960","citation_count":41,"is_preprint":false},{"pmid":"16407277","id":"PMC_16407277","title":"Membrane topology of the transporter associated with antigen processing (TAP1) within an assembled functional peptide-loading complex.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16407277","citation_count":41,"is_preprint":false},{"pmid":"8617293","id":"PMC_8617293","title":"TAP1-deficient mice select a CD8+ T cell repertoire that displays both diversity and peptide specificity.","date":"1996","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8617293","citation_count":40,"is_preprint":false},{"pmid":"8120379","id":"PMC_8120379","title":"Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells.","date":"1994","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8120379","citation_count":40,"is_preprint":false},{"pmid":"29091951","id":"PMC_29091951","title":"Downregulation of TAP1 and TAP2 in early stage breast cancer.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29091951","citation_count":39,"is_preprint":false},{"pmid":"12047747","id":"PMC_12047747","title":"Interactions formed by individually expressed TAP1 and TAP2 polypeptide subunits.","date":"2002","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12047747","citation_count":38,"is_preprint":false},{"pmid":"10975834","id":"PMC_10975834","title":"Synergistic induction of the Tap-1 gene by IFN-gamma and lipopolysaccharide in macrophages is regulated by STAT1.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10975834","citation_count":37,"is_preprint":false},{"pmid":"7843229","id":"PMC_7843229","title":"Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice.","date":"1995","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7843229","citation_count":37,"is_preprint":false},{"pmid":"29879547","id":"PMC_29879547","title":"The influence of TAP1 and TAP2 gene polymorphisms on TAP function and its inhibition by viral immune evasion proteins.","date":"2018","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29879547","citation_count":37,"is_preprint":false},{"pmid":"9260681","id":"PMC_9260681","title":"Spread of measles virus through axonal pathways into limbic structures in the brain of TAP1 -/- mice.","date":"1997","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/9260681","citation_count":36,"is_preprint":false},{"pmid":"32108992","id":"PMC_32108992","title":"Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32108992","citation_count":35,"is_preprint":false},{"pmid":"20134267","id":"PMC_20134267","title":"Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 expressing HaCaT cells: correlate with TAP-1 expression.","date":"2010","source":"International journal of gynecological cancer : official journal of the International Gynecological Cancer Society","url":"https://pubmed.ncbi.nlm.nih.gov/20134267","citation_count":35,"is_preprint":false},{"pmid":"18984863","id":"PMC_18984863","title":"Both alleles of PSF1 are required for maintenance of pool size of immature hematopoietic cells and acute bone marrow regeneration.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18984863","citation_count":34,"is_preprint":false},{"pmid":"32923135","id":"PMC_32923135","title":"Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients.","date":"2020","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/32923135","citation_count":34,"is_preprint":false},{"pmid":"16474838","id":"PMC_16474838","title":"The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16474838","citation_count":33,"is_preprint":false},{"pmid":"16624807","id":"PMC_16624807","title":"Biogenesis of functional antigenic peptide transporter TAP requires assembly of pre-existing TAP1 with newly synthesized TAP2.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16624807","citation_count":32,"is_preprint":false},{"pmid":"15219464","id":"PMC_15219464","title":"Role of TAP-1 and/or TAP-2 antigen presentation defects in tumorigenicity of mouse melanoma.","date":"2004","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15219464","citation_count":31,"is_preprint":false},{"pmid":"9776728","id":"PMC_9776728","title":"Interferon induction of TAP1: the phosphatase SHP-1 regulates crossover between the IFN-alpha/beta and the IFN-gamma signal-transduction pathways.","date":"1998","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/9776728","citation_count":31,"is_preprint":false},{"pmid":"25398693","id":"PMC_25398693","title":"Knockdown of PSF1 expression inhibits cell proliferation in lung cancer cells in vitro.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25398693","citation_count":30,"is_preprint":false},{"pmid":"9042048","id":"PMC_9042048","title":"Polymorphism in transporter antigen peptides gene (TAP1) associated with atopy in Tunisians.","date":"1997","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9042048","citation_count":29,"is_preprint":false},{"pmid":"9973386","id":"PMC_9973386","title":"Processing of HIV-1 envelope glycoprotein for class I-restricted recognition: dependence on TAP1/2 and mechanisms for cytosolic localization.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9973386","citation_count":29,"is_preprint":false},{"pmid":"8228229","id":"PMC_8228229","title":"Polymorphism in the mouse Tap-1 gene. Association with abnormal CD8+ T cell development in the nonobese nondiabetic mouse.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8228229","citation_count":28,"is_preprint":false},{"pmid":"24175803","id":"PMC_24175803","title":"Association of TAP1 and TAP2 gene polymorphisms with hematological malignancies.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/24175803","citation_count":27,"is_preprint":false},{"pmid":"17068338","id":"PMC_17068338","title":"Catalytic site modifications of TAP1 and TAP2 and their functional consequences.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17068338","citation_count":27,"is_preprint":false},{"pmid":"9724033","id":"PMC_9724033","title":"Porcine steroidogenic factor-1 gene (pSF-1) expression and analysis of embryonic pig gonads during sexual differentiation.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9724033","citation_count":26,"is_preprint":false},{"pmid":"8497259","id":"PMC_8497259","title":"TAP1, a yeast gene that activates the expression of a tRNA gene with a defective internal promoter.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8497259","citation_count":26,"is_preprint":false},{"pmid":"28700671","id":"PMC_28700671","title":"A case-control study on association of proteasome subunit beta 8 (PSMB8) and transporter associated with antigen processing 1 (TAP1) polymorphisms and their transcript levels in vitiligo from Gujarat.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28700671","citation_count":25,"is_preprint":false},{"pmid":"28477473","id":"PMC_28477473","title":"IRG1 increases MHC class I level in macrophages through STAT-TAP1 axis depending on NADPH oxidase mediated reactive oxygen species.","date":"2017","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28477473","citation_count":25,"is_preprint":false},{"pmid":"8208914","id":"PMC_8208914","title":"Analysis of HLA-class-II-encoded antigen-processing genes TAP1 and TAP2 in primary biliary cirrhosis.","date":"1994","source":"The Quarterly journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8208914","citation_count":25,"is_preprint":false},{"pmid":"12047361","id":"PMC_12047361","title":"TAP1 and TAP2 gene polymorphism in rheumatoid arthritis in a population in eastern France.","date":"2002","source":"European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/12047361","citation_count":24,"is_preprint":false},{"pmid":"7578413","id":"PMC_7578413","title":"Tap-1 and Tap-2 gene therapy selectively restores conformationally dependent HLA Class I expression in type I diabetic cells.","date":"1995","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/7578413","citation_count":24,"is_preprint":false},{"pmid":"9001385","id":"PMC_9001385","title":"The MHC-encoded TAP1/LMP2 bidirectional promoter is down-regulated in highly oncogenic adenovirus type 12 transformed cells.","date":"1997","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9001385","citation_count":24,"is_preprint":false},{"pmid":"32825219","id":"PMC_32825219","title":"Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32825219","citation_count":23,"is_preprint":false},{"pmid":"12777979","id":"PMC_12777979","title":"Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression.","date":"2003","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/12777979","citation_count":23,"is_preprint":false},{"pmid":"9669329","id":"PMC_9669329","title":"Genomic organization of six tomato polygalacturonases and 5' upstream sequence identity with tap1 and win2 genes.","date":"1998","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/9669329","citation_count":22,"is_preprint":false},{"pmid":"18941254","id":"PMC_18941254","title":"Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18941254","citation_count":22,"is_preprint":false},{"pmid":"11169961","id":"PMC_11169961","title":"Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11169961","citation_count":22,"is_preprint":false},{"pmid":"22104481","id":"PMC_22104481","title":"Isolation, identification and characterization of a novel triazophos-degrading Bacillus sp. (TAP-1).","date":"2011","source":"Microbiological research","url":"https://pubmed.ncbi.nlm.nih.gov/22104481","citation_count":21,"is_preprint":false},{"pmid":"26205887","id":"PMC_26205887","title":"Heterozygote of TAP1 Codon637 decreases susceptibility to HPV infection but increases susceptibility to esophageal cancer among the Kazakh populations.","date":"2015","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/26205887","citation_count":21,"is_preprint":false},{"pmid":"26996113","id":"PMC_26996113","title":"Association of TAP1 and TAP2 Gene Polymorphisms with Susceptibility to Pulmonary Tuberculosis.","date":"2016","source":"Iranian journal of allergy, asthma, and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26996113","citation_count":20,"is_preprint":false},{"pmid":"11468516","id":"PMC_11468516","title":"Reduced expression of TAP-1 and TAP-2 in posterior uveal melanoma is associated with progression to metastatic disease.","date":"2001","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/11468516","citation_count":20,"is_preprint":false},{"pmid":"8061113","id":"PMC_8061113","title":"Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.","date":"1994","source":"Lymphokine and cytokine research","url":"https://pubmed.ncbi.nlm.nih.gov/8061113","citation_count":20,"is_preprint":false},{"pmid":"7860359","id":"PMC_7860359","title":"Susceptibility to alloimmunization to platelet HPA-1a antigen involves TAP1 polymorphism.","date":"1994","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7860359","citation_count":19,"is_preprint":false},{"pmid":"9111005","id":"PMC_9111005","title":"Membrane topology of the ATP-binding cassette transporter associated with antigen presentation (Tap1) expressed in Escherichia coli.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9111005","citation_count":19,"is_preprint":false},{"pmid":"11194890","id":"PMC_11194890","title":"Polymorphisms in inflammation genes (angiotensinogen, TAP1 and TNF-beta) in psoriasis.","date":"2000","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/11194890","citation_count":18,"is_preprint":false},{"pmid":"33925089","id":"PMC_33925089","title":"Broadly Antiviral Activities of TAP1 through Activating the TBK1-IRF3-Mediated Type I Interferon Production.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33925089","citation_count":18,"is_preprint":false},{"pmid":"12505156","id":"PMC_12505156","title":"Functional cysteine-less subunits of the transporter associated with antigen processing (TAP1 and TAP2) by de novo gene assembly.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12505156","citation_count":18,"is_preprint":false},{"pmid":"22462603","id":"PMC_22462603","title":"Fruit-specific overexpression of wound-induced tap1 under E8 promoter in tomato confers resistance to fungal pathogens at ripening stage.","date":"2012","source":"Physiologia plantarum","url":"https://pubmed.ncbi.nlm.nih.gov/22462603","citation_count":18,"is_preprint":false},{"pmid":"10203023","id":"PMC_10203023","title":"Cell surface expression of HLA-E molecules on PBMC from a TAP1-deficient patient.","date":"1999","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/10203023","citation_count":17,"is_preprint":false},{"pmid":"8643655","id":"PMC_8643655","title":"Biosynthesis of major histocompatibility complex molecules and generation of T cells in Ii TAP1 double-mutant mice.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8643655","citation_count":17,"is_preprint":false},{"pmid":"17418234","id":"PMC_17418234","title":"Modulation of the antigenic peptide transporter TAP by recombinant antibodies binding to the last five residues of TAP1.","date":"2007","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17418234","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49876,"output_tokens":6659,"usd":0.124757},"stage2":{"model":"claude-opus-4-6","input_tokens":10472,"output_tokens":3564,"usd":0.21219},"total_usd":0.336947,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"TAP1 is required for stable assembly and intracellular transport of MHC class I molecules; TAP1-deficient mice show severely reduced surface class I molecules and cannot present cytosolic antigens to class I-restricted cytotoxic T cells.\",\n      \"method\": \"Gene knockout (embryonic stem cell technology) with functional assays for antigen presentation and surface MHC class I expression\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — clean KO with multiple defined cellular phenotypes; foundational paper with 622 citations\",\n      \"pmids\": [\"1473153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"TAP1 is part of an ATP-dependent, sequence-specific peptide translocator; peptide translocation in vitro requires TAP1 and is both ATP-dependent and peptide selective.\",\n      \"method\": \"Cell-free in vitro peptide translocation assay using TAP1-deficient cell membranes\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted cell-free system demonstrating ATP-dependent, sequence-specific transport\",\n      \"pmids\": [\"8348620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Both TAP1 and TAP2 subunits contribute to the peptide-recognition site (both are photolabeled by photopeptide analogues), but MHC class I/β2-microglobulin dimers associate specifically with TAP1 but not TAP2, indicating the MHC class I interaction site resides on TAP1. Efficient peptide binding requires coexpression of both TAP1 and TAP2, supporting heterodimeric function.\",\n      \"method\": \"Photoaffinity labeling of TAP subunits, co-immunoprecipitation of MHC class I with individual TAP subunits in transfectant cell lines\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (photoaffinity labeling + co-IP) in same study\",\n      \"pmids\": [\"7809108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Introduction of the rat TAP1 gene alone into TAP1/TAP2-deficient CMT.64 cells restores CTL recognition of virus-infected cells, indicating that a TAP1 homodimer can partially translocate peptides into the ER.\",\n      \"method\": \"Gene transfection of TAP1 into antigen-processing deficient cell lines followed by CTL cytotoxicity assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean gene rescue with defined functional readout; single lab\",\n      \"pmids\": [\"7931074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"TAP1 and LMP2 are divergently transcribed from a shared bidirectional promoter (~593 bp); an NF-κB element proximal to the TAP1 gene is required for TNF-α induction of both TAP1 and LMP2, and an adjacent GC box (binding Sp1) is required for basal expression of both genes.\",\n      \"method\": \"Bidirectional reporter assays, site-specific mutagenesis, in vivo genomic footprinting, in vitro binding studies (EMSA)\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including mutagenesis, reporter assays, and footprinting\",\n      \"pmids\": [\"7699330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IFN-γ induction of TAP1 and LMP2 is mediated by IRF-1 binding to an IRF-E element in the shared bidirectional promoter; TAP1 and LMP2 expression are both greatly reduced in IRF-1-deficient mice, which also show reduced surface MHC class I and CD8+ T cells.\",\n      \"method\": \"In vivo footprinting, gel shift analysis (EMSA), gene knockout mice (IRF-1-/-) with functional readouts\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple methods including in vivo footprinting, EMSA, and KO mice\",\n      \"pmids\": [\"8885869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"IFN-γ induces TAP1 more rapidly than HLA class I by activating the TAP1 promoter via a GAS element bound by STAT1α (activated faster than IRF-1); the GAS element is necessary and sufficient for rapid IFN-γ response of TAP1.\",\n      \"method\": \"Promoter-reporter transfection assays, GAS element mutagenesis, kinetic analysis of STAT1α vs. IRF-1 activation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — promoter mutagenesis combined with kinetic signaling analysis; clear mechanistic dissection\",\n      \"pmids\": [\"8617938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A functionally defective TAP1 allele (R659Q near the ATP-binding site) in a human small cell lung cancer cell line results in defective peptide transport and loss of MHC class I antigen presentation, restored by transfection of functional TAP1.\",\n      \"method\": \"Sequencing of TAP1 alleles, peptide binding assays, antigen presentation assays, gene transfection rescue\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including functional rescue by transfection\",\n      \"pmids\": [\"8640228\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"EBV-encoded vIL-10 (and human IL-10) specifically downregulates expression of TAP1 and LMP2 (but not TAP2 or LMP7) in B lymphocytes, impairing peptide transport into the ER and reducing surface MHC class I expression.\",\n      \"method\": \"Gene expression analysis, TAP-specific peptide transporter assay, surface MHC class I measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (expression, functional transport assay, surface MHC); strong specificity controls\",\n      \"pmids\": [\"9310490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TAP1 membrane topology consists of eight transmembrane segments (based on E. coli expression of TAP1-β-lactamase fusions), with the N and C termini (including the nucleotide-binding domain) in the cytoplasm and several large loops exposed in the ER lumen.\",\n      \"method\": \"Reporter fusion (β-lactamase) topology mapping in E. coli\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic topology mapping; later refined by cysteine-scanning study\",\n      \"pmids\": [\"9111005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"IFN-α/β and IFN-γ both regulate TAP1 through GAS and ISRE elements; the phosphatase SHP-1 (expressed at lower levels in endothelial cells than HeLa cells) regulates crossover signaling between IFN-α/β and IFN-γ pathways at the TAP1 promoter.\",\n      \"method\": \"Promoter-reporter assays, overexpression of dominant negative SHP-1, kinase/signaling analysis in endothelial cells vs. HeLa cells\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of signaling crossover with functional promoter readout; single lab\",\n      \"pmids\": [\"9776728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p53 directly induces TAP1 expression through a p53-responsive element in the TAP1 gene; p53-induced TAP1 enhances peptide transport and surface MHC class I-peptide complex expression, with cooperation between p53 and IFN-γ in activating the MHC class I pathway.\",\n      \"method\": \"Reporter assays with p53-responsive element, p53/p73 transfection, peptide transport assays, surface MHC class I measurement\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods including reporter assays, functional transport assay, and surface expression\",\n      \"pmids\": [\"10618714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TAP1 deficiency in human patients causes unstable HLA class I molecules retained in the endoplasmic reticulum, leading to HLA class I deficiency syndrome (bare lymphocyte syndrome type I) with lung and skin manifestations.\",\n      \"method\": \"Clinical patient analysis, protein biochemistry, HLA class I stability assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function with defined molecular phenotype (ER retention of class I)\",\n      \"pmids\": [\"10074495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Walker A lysine mutations in the nucleotide-binding domains of TAP1 (K544M) and TAP2 (K509M) block peptide translocation but not peptide binding; nucleotide binding to TAP1 is not required for peptide binding, and both intact NBDs are needed for efficient peptide translocation.\",\n      \"method\": \"Site-directed mutagenesis, nucleotide binding assays, fluorescence quenching peptide binding assays, peptide translocation assays in insect cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro mutagenesis with multiple functional assays (binding and translocation) dissecting distinct NBD roles\",\n      \"pmids\": [\"11099504\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The ABC ATPase domain of TAP1 (cTAP1) forms an L-shaped molecule with a RecA-like domain and a small α-helical domain; the ADP diphosphate group interacts with the P-loop; residues involved in γ-phosphate binding and hydrolysis show flexibility in the ADP-bound state; TAP1 differs from TAP2 in the nucleotide-binding site, potentially explaining asymmetry during peptide transport.\",\n      \"method\": \"X-ray crystallography of the C-terminal ABC ATPase domain of TAP1 bound to ADP\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with functional comparison across subfamily members\",\n      \"pmids\": [\"11532960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"HPV type 11 E7 protein physically interacts with TAP1 (co-immunoprecipitation with calreticulin and TAP1; anti-TAP1 antibody co-precipitates E7) and inhibits ATP-dependent peptide transport in vitro.\",\n      \"method\": \"Co-immunoprecipitation, in vitro ATP-dependent peptide transport assay with purified HPV11 E7 protein\",\n      \"journal\": \"Clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding by co-IP and in vitro inhibition of transport confirmed\",\n      \"pmids\": [\"11580231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Tapasin interacts with the membrane-spanning domains (not the nucleotide-binding domains) of both TAP1 and TAP2; tapasin is not required for high-affinity peptide binding to TAP but enhances structural/thermal stability of TAP1·TAP2 complexes, explaining how tapasin increases TAP protein expression levels.\",\n      \"method\": \"Co-immunoprecipitation, domain-swapped chimeras, truncated TAP constructs, thermostability assays in insect cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple domain constructs with functional assays identify the interaction interface and functional consequence\",\n      \"pmids\": [\"12213826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A single-nucleotide deletion at position +1489 of TAP1 in a melanoma cell line causes rapid degradation of TAP1 mRNA (>2-fold decrease in half-life) via a non-NMD pathway, leading to loss of TAP1 expression and MHC class I downregulation despite active TAP1 transcription.\",\n      \"method\": \"Tet-Off inducible expression system to measure mRNA half-life, cycloheximide chase, sequencing\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — quantitative mRNA half-life measurement with mechanistic controls ruling out NMD\",\n      \"pmids\": [\"12582163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"IFN-γ induction of murine Tap-1 and Lmp-2 in macrophages requires both STAT1 (binding the proximal GAS box rapidly) and IRF-1 (binding the IRF-1 box after ≥2h); in STAT1 knockout macrophages, IFN-γ fails to induce Tap-1 or Lmp-2.\",\n      \"method\": \"Promoter deletion analysis, EMSA with nuclear extracts, gene knockout mice (STAT1-/-), IFN-γ stimulation assays\",\n      \"journal\": \"Genes and immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple methods including KO mice and EMSA identifying sequential transcription factor binding\",\n      \"pmids\": [\"14735146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TAP1 contains ten transmembrane segments within an assembled functional peptide-loading complex, placing both N and C termini in the cytosol; the TM domain consists of a core of six TMs (conserved among ABC transporters) plus a unique N-terminal domain of four TMs essential for tapasin binding and peptide-loading complex assembly.\",\n      \"method\": \"Cysteine-scanning mutagenesis with membrane-impermeable thiol-specific fluorophores in semi-permeabilized living cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic cysteine-scanning in intact functional complex provides refined topology map with functional validation\",\n      \"pmids\": [\"16407277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TAP biogenesis requires assembly of pre-existing TAP1 with newly synthesized TAP2 (not vice versa); the pore-forming core transmembrane domain of TAP2 is necessary and sufficient for assembly with pre-existing TAP1; TAP2 is rapidly degraded when expressed alone but is stabilized upon heterodimerization with TAP1.\",\n      \"method\": \"In vitro expression system, pulse-chase analysis, domain truncation of TAP2, functional transport assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with domain mapping and functional readout\",\n      \"pmids\": [\"16624807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The catalytic site of TAP1 contains non-consensus residues (Asp668 in Walker B, Gln701 in switch region) that attenuate ATPase activity at the TAP1 nucleotide-binding site; the TAP2 site (with Glu632 and His661) is the primary catalytically active site driving peptide transport.\",\n      \"method\": \"Site-directed mutagenesis of catalytic site residues, peptide translocation assays, MHC class I surface expression assays in insect cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic mutagenesis of both catalytic sites with quantitative functional readouts\",\n      \"pmids\": [\"17068338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The C terminus of TAP1 (last five residues) modulates TAP function as part of the dimer interface of the nucleotide-binding domains; antibody binding to this region arrests TAP in a peptide transport-incompetent conformation while ATP and peptide binding to TAP remain unaffected.\",\n      \"method\": \"Recombinant antibody (Fv and Fab) generation, epitope mapping by solid-supported peptide arrays, surface plasmon resonance, peptide transport assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional consequence of C-terminus binding demonstrated; single lab\",\n      \"pmids\": [\"17418234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TAP1 indirectly regulates CD4+ T cell priming during Toxoplasma gondii infection by controlling NK cell IFN-γ production; adoptive transfer of IFN-γ-competent NK cells into TAP1-/- mice restores CD4+ T cell IFN-γ responses, placing TAP1 upstream of NK cell licensing in innate immune signaling.\",\n      \"method\": \"TAP1-/- mouse infection model, NK cell depletion, adoptive transfer of IFN-γ+/+ vs. IFN-γ-/- NK cells, flow cytometry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis by adoptive transfer with mechanistic dissection of NK-CD4 axis\",\n      \"pmids\": [\"17923502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Low basal TAP1 expression in SCCHN cells is primarily regulated by deficient STAT1 phosphorylation (pSTAT1); STAT1 knockdown reduces IFN-γ-mediated TAP1 expression and CTL recognition; pSTAT3 does not interfere with IFN-γ-induced STAT1 binding to the TAP1 promoter or TAP1 expression.\",\n      \"method\": \"STAT1 knockdown/overexpression, IFN-γ stimulation, CTL recognition assays, chromatin immunoprecipitation (STAT1 binding to TAP1 promoter)\",\n      \"journal\": \"Cancer immunology, immunotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods including ChIP for STAT1 at TAP1 promoter; single lab\",\n      \"pmids\": [\"21207025\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TAP1 (ABCB2) is a downstream transcriptional target of SHH/GLI1/2 hedgehog signaling; GLI1/2 binds to the TAP1 promoter, and TAP1 mediates hedgehog-induced drug resistance in pancreatic ductal adenocarcinoma cells.\",\n      \"method\": \"ChIP and promoter binding assays (GLI-binding site validation), RNAi knockdown of GLI1 and TAP1, in vitro and in vivo tumor drug sensitivity assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — GLI binding to TAP1 promoter confirmed by molecular assay with functional drug resistance readout; single lab\",\n      \"pmids\": [\"23340176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Naturally occurring TAP1 polymorphic variants have no or limited effect on peptide transport or MHC class I expression, and herpesvirus-encoded TAP inhibitors (HCMV US6, HSV-1 ICP47, EBV BNLF2a) inhibit a broad spectrum of TAP variants without allele-specific resistance.\",\n      \"method\": \"Peptide transport assays, MHC class I surface expression assays across TAP1/TAP2 variant-expressing cells, viral TAP inhibitor inhibition assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic functional testing across natural variants with multiple inhibitors; single lab\",\n      \"pmids\": [\"29879547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-200a-5p directly targets the 3'-UTR of TAP1, reducing TAP1 protein levels and HLA class I surface expression in melanoma cells, leading to enhanced NK cell sensitivity; miR-200a-5p expression is inversely correlated with TAP1 protein in melanoma cell lines and primary lesions.\",\n      \"method\": \"Luciferase reporter assay (miR binding to TAP1 3'-UTR), miR overexpression/inhibitor experiments, surface HLA-I measurement, NK cell killing assay\",\n      \"journal\": \"Oncoimmunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — validated by luciferase reporter assay plus functional consequences in multiple assays\",\n      \"pmids\": [\"32923135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Hedgehog transcription factor GLI1/2 directly binds to the TAP1 promoter and transcriptionally controls TAP1 expression in hepatocellular carcinoma, mediating drug resistance to sorafenib, doxorubicin, and cisplatin.\",\n      \"method\": \"ChIP/promoter binding assays (GLI-binding site in TAP1 promoter), RNAi of GLI1 and TAP1, drug sensitivity assays in vitro and in vivo\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding validated with functional drug resistance readout; single lab\",\n      \"pmids\": [\"32108992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TAP1 promotes IFN-β production by activating TBK1 and IRF3 signaling, conferring broad antiviral activity against multiple viruses (HSV-1, AdV, VSV, DENV, ZIKV, influenza) independent of its antigen presentation function.\",\n      \"method\": \"Loss-of-function and gain-of-function experiments, IFN-β reporter assays, TBK1/IRF3 activation assays, viral infection assays\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal experiments; novel function claim requires independent replication\",\n      \"pmids\": [\"33925089\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TAP1 (ABCB2) is an ER-resident ABC transporter that forms a heterodimer with TAP2, using ATP hydrolysis (driven primarily by the TAP2 nucleotide-binding site, with TAP1's NBD playing an asymmetric, attenuated catalytic role) to translocate cytosolic antigenic peptides across the ER membrane for loading onto MHC class I molecules; its expression is transcriptionally regulated by a shared bidirectional promoter with LMP2 via STAT1, IRF-1, NF-κB, and Sp1 elements downstream of IFN-γ/TNF-α signaling, TAP1 protein stability depends on heterodimerization with TAP2 (stabilized by tapasin binding to the N-terminal four-TM domain), MHC class I molecules interact specifically with TAP1 (not TAP2), and TAP1 is targeted by viral immune evasion proteins (e.g., HPV E7, HSV ICP47) and post-transcriptionally regulated by miRNAs (miR-200a-5p, miR-26b-5p, miR-21-3p), with an additional emerging role in innate antiviral signaling through TBK1-IRF3-mediated IFN-β production.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TAP1 is an ER-resident ABC transporter subunit that heterodimerizes with TAP2 to form an ATP-dependent peptide translocator essential for loading antigenic peptides onto MHC class I molecules and sustaining cell-surface class I expression [PMID:1473153, PMID:8348620]. Both subunits contribute to the peptide-binding site, but MHC class I heavy chain–β2-microglobulin dimers associate specifically with TAP1; the TAP1 nucleotide-binding domain adopts a non-consensus catalytic configuration with attenuated ATPase activity, making the TAP2 NBD the primary driver of transport, while the N-terminal four-transmembrane domain unique to TAP1 mediates tapasin binding and peptide-loading complex assembly [PMID:7809108, PMID:17068338, PMID:16407277]. Transcription of TAP1 is governed by a bidirectional promoter shared with LMP2, integrating IFN-γ signals through sequential STAT1 (GAS element) and IRF-1 engagement, NF-κB-dependent TNF-α responses, and p53-mediated induction, while post-transcriptionally TAP1 is regulated by miR-200a-5p targeting its 3′-UTR [PMID:7699330, PMID:8617938, PMID:8885869, PMID:10618714, PMID:32923135]. Loss-of-function mutations in TAP1 cause bare lymphocyte syndrome type I (HLA class I deficiency) with pulmonary and cutaneous disease [PMID:10074495].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Establishing that TAP1 is non-redundant for MHC class I surface expression and antigen presentation resolved whether this MHC-linked gene was truly essential for the class I pathway.\",\n      \"evidence\": \"TAP1 knockout mice generated by ES cell technology showed severely reduced surface class I and abolished CTL recognition of cytosolic antigens\",\n      \"pmids\": [\"1473153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of peptide transport not yet demonstrated biochemically\", \"Relative contributions of TAP1 vs TAP2 unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrating ATP-dependent, sequence-selective peptide translocation in a cell-free system established TAP1 as part of a bona fide active transporter rather than a passive channel.\",\n      \"evidence\": \"In vitro peptide translocation assay using membranes from TAP1-deficient cells reconstituted with TAP1\",\n      \"pmids\": [\"8348620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TAP1 alone or TAP1–TAP2 heterodimer is the functional unit not resolved\", \"Substrate selectivity rules incomplete\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Photoaffinity labeling and co-IP showed that both TAP1 and TAP2 contact peptide, but MHC class I associates specifically with TAP1, assigning distinct roles within the heterodimer.\",\n      \"evidence\": \"Photoaffinity peptide labeling of individual TAP subunits and co-immunoprecipitation of MHC class I with TAP1 but not TAP2 in transfectant lines\",\n      \"pmids\": [\"7809108\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for selective MHC class I–TAP1 interaction unknown\", \"Stoichiometry of MHC class I–TAP complex not determined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of the shared bidirectional TAP1–LMP2 promoter with NF-κB and Sp1 elements explained coordinated regulation of antigen processing genes by inflammatory cytokines.\",\n      \"evidence\": \"Bidirectional reporter assays, site-directed mutagenesis of NF-κB and GC elements, in vivo footprinting, and EMSA\",\n      \"pmids\": [\"7699330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of transcription factors using this promoter not catalogued\", \"Chromatin context and epigenetic regulation not addressed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Sequential engagement of STAT1 (via GAS element) and IRF-1 (via IRF-E) explained how IFN-γ rapidly and sustainably induces TAP1, with KO mice confirming both factors are required in vivo.\",\n      \"evidence\": \"Promoter mutagenesis, kinetic signaling analysis of STAT1α vs IRF-1 activation; IRF-1−/− and later STAT1−/− mice showing loss of TAP1 induction\",\n      \"pmids\": [\"8617938\", \"8885869\", \"14735146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Epigenetic mechanisms governing promoter accessibility not explored\", \"Whether other STAT family members compensate partially unclear\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of a human TAP1 point mutation (R659Q) near the ATP-binding site that abolished peptide transport in a lung cancer line established that single residue changes in the NBD are sufficient to eliminate function.\",\n      \"evidence\": \"Sequencing, peptide binding assays, and gene transfection rescue of antigen presentation in a small cell lung cancer line\",\n      \"pmids\": [\"8640228\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this mutation affects ATP binding, hydrolysis, or conformational coupling not distinguished\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that p53 directly transactivates TAP1 via a p53-responsive element linked tumor suppression to immune surveillance through antigen processing.\",\n      \"evidence\": \"Reporter assays with p53-responsive element, p53 transfection, peptide transport and surface MHC class I assays\",\n      \"pmids\": [\"10618714\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p53 loss in tumors is a dominant mechanism of TAP1 silencing in vivo not tested\", \"Interaction with other p53 family members (p73) only partially explored\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"TAP1 deficiency in humans was shown to cause bare lymphocyte syndrome type I with ER-retained unstable HLA class I, directly linking TAP1 loss to a defined immunodeficiency.\",\n      \"evidence\": \"Clinical analysis of TAP1-deficient patients with biochemical demonstration of ER-retained class I molecules\",\n      \"pmids\": [\"10074495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype correlation across different TAP1 mutations incomplete\", \"Why patients develop granulomatous lung disease specifically not mechanistically explained\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The crystal structure of the TAP1 NBD revealed an L-shaped RecA-like/α-helical architecture with non-consensus catalytic residues, providing the structural basis for asymmetric ATPase activity in the TAP heterodimer.\",\n      \"evidence\": \"X-ray crystallography of the C-terminal ATPase domain of TAP1 bound to ADP\",\n      \"pmids\": [\"11532960\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length TAP1–TAP2 heterodimer structure not available\", \"Conformational changes during the transport cycle not captured\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"HPV E7 was shown to physically bind TAP1 and inhibit ATP-dependent peptide transport, establishing a viral immune evasion mechanism directly targeting the transporter.\",\n      \"evidence\": \"Co-immunoprecipitation of HPV11 E7 with TAP1, in vitro peptide transport inhibition assay\",\n      \"pmids\": [\"11580231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interface on TAP1 not mapped\", \"Mechanism of transport inhibition (competitive vs allosteric) not determined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Tapasin was found to bind the transmembrane domains (not NBDs) of TAP1 and TAP2 and to stabilize the heterodimer thermally, explaining how tapasin enhances TAP protein levels without affecting peptide binding affinity.\",\n      \"evidence\": \"Co-immunoprecipitation with domain-swapped chimeras, truncated TAP constructs, and thermostability assays in insect cells\",\n      \"pmids\": [\"12213826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise TM helices mediating tapasin contact not identified\", \"How tapasin stabilization coordinates with peptide loading kinetics unclear\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Refined topology mapping established TAP1 as a 10-TM protein with a unique N-terminal four-TM domain essential for tapasin binding and peptide-loading complex assembly, distinguishing it from canonical six-TM ABC transporters.\",\n      \"evidence\": \"Cysteine-scanning mutagenesis with membrane-impermeable fluorophores in semi-permeabilized cells expressing functional peptide-loading complex\",\n      \"pmids\": [\"16407277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of the N-terminal four-TM domain not available\", \"Whether the N-terminal domain contacts MHC class I directly not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mutagenesis of both catalytic sites showed TAP1's NBD has attenuated ATPase activity due to non-consensus Walker B (Asp668) and switch (Gln701) residues, assigning TAP2's NBD as the primary catalytic engine for peptide translocation.\",\n      \"evidence\": \"Site-directed mutagenesis of catalytic residues in both NBDs, quantitative peptide translocation and MHC class I surface expression assays\",\n      \"pmids\": [\"17068338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TAP1 NBD contributes regulatory ATP binding without hydrolysis not fully resolved\", \"Coupling mechanism between TAP2 hydrolysis and conformational switching of TAP1 TMDs not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"miR-200a-5p was validated as a direct post-transcriptional repressor of TAP1 via its 3′-UTR, revealing a microRNA-based mechanism for immune evasion in melanoma.\",\n      \"evidence\": \"Luciferase reporter assay confirming miR-200a-5p binding to TAP1 3′-UTR, miR overexpression/inhibition with HLA-I surface measurement and NK cell killing assays\",\n      \"pmids\": [\"32923135\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other miRNAs (miR-26b-5p, miR-21-3p) act additively on TAP1 not established\", \"In vivo relevance of miR-200a-5p–TAP1 axis in tumor immune evasion not demonstrated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"A presentation-independent innate immune role was proposed for TAP1, activating TBK1–IRF3 signaling to induce IFN-β and confer broad antiviral activity.\",\n      \"evidence\": \"Loss- and gain-of-function experiments, IFN-β reporter assays, TBK1/IRF3 activation, and multi-virus infection assays\",\n      \"pmids\": [\"33925089\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Not independently replicated\", \"Molecular mechanism by which TAP1 activates TBK1 unknown\", \"Whether this function requires TAP2 not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of the full-length TAP1–TAP2 heterodimer in complex with tapasin and MHC class I capturing multiple conformational states during the transport cycle remains unresolved, as does the precise mechanism by which TAP1 activates TBK1–IRF3 signaling independently of peptide transport.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No full transport-cycle structural snapshots of the human TAP1–TAP2–tapasin–MHC I complex\", \"Mechanism of TAP1-mediated TBK1 activation uncharacterized\", \"Relative contributions of transcriptional vs post-transcriptional TAP1 silencing in tumor immune evasion in vivo not quantified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [1, 13, 14, 21]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 3, 13, 21]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [9, 12, 19]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 12, 23]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [1, 13, 21]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5, 6, 11, 18]}\n    ],\n    \"complexes\": [\n      \"TAP1–TAP2 heterodimer\",\n      \"MHC class I peptide-loading complex\"\n    ],\n    \"partners\": [\n      \"TAP2\",\n      \"TAPBP\",\n      \"B2M\",\n      \"IRF1\",\n      \"STAT1\",\n      \"GLI1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}